Cardiovascular Disease Prevention and Therapy in Women With Type 2 Diabetes

References

• American Heart Association . Cardiovascular disease & diabetes (2015). (Accessed 11February2021) www.heart.org/HEARTORG/Conditions/More/Diabetes/WhyDiabetesMatterCardiovascular-Disease-Diabetes_UCM_313865_Article.jsp/#.Wh_-eNKg_RY
   Google Scholar
• Cho NH , ShawJE, KarurangaSet al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract., 138, 271–281 (2018).
   PubMed Web of Science ®Google Scholar
• NCD Risk Factor Collaboration . Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet, 387(10027), 1513–1530 (2016).
   PubMed Web of Science ®Google Scholar
• Peters SA , HuxleyRR, WoodwardM. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia, 57, 1542–1551 (2014).
   PubMed Web of Science ®Google Scholar
• Mattioli AV , SciomerS, MoscucciFet al. Cardiovascular prevention in women: a narrative review from the Italian Society of Cardiology working groups on ‘cardiovascular prevention, hypertension and peripheral circulation’ and on ‘women disease.’ J. Cardiovasc. Med., 20, 575–583 (2019).
   Google Scholar
• D'Ascenzi F , SciaccalugaC, CameliMet al. When should cardiovascular prevention begin? The importance of antenatal, perinatal and primordial prevention. Eur. J. Prev. Cardiol. doi:10.1177/2047487319893832 (2019) ( Epub ahead of print).
   Google Scholar
• Peters SA , HuxleyRR, WoodwardM. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet, 383(9933), 1973–1980 (2014).
   PubMed Web of Science ®Google Scholar
• Goossens GH , JockenJWE, BlaakEE. Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver. Nat. Rev. Endocrinol., 17(1), 47–66 (2021).
   PubMed Web of Science ®Google Scholar
• Strain WD , PaldániusPM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc. Diabetol., 17(1), 57 (2018).
   PubMedGoogle Scholar
• Brohall G , OdénA, FagerbergB. Carotid artery intima-media thickness in patients with type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet. Med., 23, 609–616 (2006).
   PubMed Web of Science ®Google Scholar
• Rizzoni D , PorteriE, GuelfiDet al. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation, 103, 1238–1244 (2001).
   PubMed Web of Science ®Google Scholar
• Balla S , GomezSE, RodriguezF. Disparities in cardiovascular care and outcomes for women from racial/ethnic minority backgrounds. Curr. Treat. Options Cardiovasc. Med., 22(12), 75 (2020).
   PubMed Web of Science ®Google Scholar
• Mattioli AV , PintiM, FarinettiA, NasiM. Obesity risk during collective quarantine for the COVID-19 epidemic. Obes. Med., 20, 100263 (2020).
   Google Scholar
• Maggio CA , Pi-SunyerFX. Obesity and type 2 diabetes. Endocrinol. Metab. Clin. North Am., 32(4), 805–822 (2003).
   PubMed Web of Science ®Google Scholar
• Cosentino F , GrantPJ, AboyansVet al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J., 41(2), 255–323 (2020).
   PubMed Web of Science ®Google Scholar
• Valensi P , LorgisL, CottinY. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. Arch. Cardiovasc. Dis., 104, 178–188 (2011).
   PubMed Web of Science ®Google Scholar
• Henning RJ . Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol., 14(6), 491–509 (2018).
   PubMedGoogle Scholar
• Maffei S , CugusiL, MeloniAet al. IGENDA protocol: gender differences in awareness, knowledge and perception of cardiovascular risk: an Italian multicenter study. J. Cardiovasc. Med., 20(5), 278–283 (2019).
   Google Scholar
• Hammond J , SalamonsonY, DavidsonPet al. Why do women underestimate the risk of cardiac disease? A literature review. Aust. Crit. Care, 20, 53–59 (2007).
   PubMedGoogle Scholar
• Kusnoor AV , FergusonAD, FalikR. Ischemic heart disease in women: a review for primary care physicians. South Med. J., 104, 200–204 (2011).
   PubMed Web of Science ®Google Scholar
• Sciomer S , MoscucciF, MaffeiS, GallinaS, MattioliAV. Prevention of cardiovascular risk factors in women: the lifestyle paradox and stereotypes we need to defeat. Eur. J. Prev. Cardiol., 26(6), 609–610 (2019).
   PubMed Web of Science ®Google Scholar
• Woodward M . Cardiovascular disease and the female disadvantage. Int. J. Environ. Res. Public Health, 16, 1165 (2019).
   PubMed Web of Science ®Google Scholar
• Maffei S , GuiducciL, CugusiLet al. Women-specific predictors of cardiovascular disease risk – new paradigms. Int. J. Cardiol., 286, 190–197 (2019).
   PubMed Web of Science ®Google Scholar
• Bellamy L , CasasJP, HingoraniAD, WilliamsD. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet, 373, 1773–1779 (2009).
   PubMed Web of Science ®Google Scholar
• Carr DB , UtzschneiderKM, HullRLet al. Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. Diabetes Care, 29, 2078–2083 (2006).
   PubMed Web of Science ®Google Scholar
• Humphries KH , IzadnegahdarM, SedlakTet al. Sex differences in cardiovascular disease – impact on care and outcomes. Front. Neuroendocrinol., 46, 46–70 (2017).
   PubMed Web of Science ®Google Scholar
• Lee CMY , MnatzaganianG, WoodwardMet al. Sex disparities in the management of coronary heart disease in general practices in Australia. Heart, 105, 1898–1904 (2019).
   PubMed Web of Science ®Google Scholar
• Turnbull F , ArimaH, HeeleyEet al. Gender disparities in the assessment and management of cardiovascular risk in primary care: the AusHEART study. Eur. J. Cardiovasc. Prev. Rehabil., 18, 498–503 (2011).
   PubMedGoogle Scholar
• Manteuffel M , WilliamsS, ChenWet al. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J. Womens Health, 23, 112–119 (2014).
   PubMed Web of Science ®Google Scholar
• Abuful A , GidronY, HenkinY. Physicians’ attitudes toward preventive therapy for coronary artery disease: is there a gender bias?Clin. Cardiol., 28, 389–393 (2005).
   PubMed Web of Science ®Google Scholar
• Stone NJ , RobinsonJG, LichtensteinAHet al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 129(25 Suppl. 2), S1–S45 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang H , PlutzkyJ, ShubinaM, TurchinA. Drivers of the sex disparity in statin therapy in patients with coronary artery disease: a cohort study. PLoS One, 11(5), e0155228 (2016).
   PubMed Web of Science ®Google Scholar
• Berger JS , RoncaglioniMC, AvanziniF, PangrazziI, TognoniG, BrownDL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA, 295, 306–313 (2006).
   PubMed Web of Science ®Google Scholar
• Mattioli AV , ManentiA, FarinettiA. Sex differences in adherence to guidelines in aspirin prescription in a population of low-risk cardiovascular patients. Eur. J. Prev. Cardiol., 25(6), 606–607 (2018).
   PubMed Web of Science ®Google Scholar
• Gaziano JM , BrotonsC, CoppolecchiaRet al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet, 392, 1036–1046 (2018).
   PubMed Web of Science ®Google Scholar
• Bowman L , MafhamM, WallendszusKet al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N. Engl. J. Med., 379, 1529–1539 (2018).
   PubMed Web of Science ®Google Scholar
• Rothwell PM , CookNR, GazianoJMet al. Effects of aspirin on risks of vascular events and cancer according to body weight and dose: analysis of individual patient data from randomised trials. Lancet, 392, 387–399 (2018).
   PubMed Web of Science ®Google Scholar
• Rocca B , FoxKAA, AjjanRAet al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur. Heart J., 39, 1672–1686 (2018).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association . 4. Lifestyle management: Standards of Medical Care in Diabetes – 2018. Diabetes Care, 41(Suppl. 1), S38–S50 (2018).
   PubMedGoogle Scholar
• Evert AB , BoucherJL, CypressMet al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care, 37, S120S143 (2014).
   Web of Science ®Google Scholar
• Balk EM , EarleyA, RamanG, AvendanoEA, PittasAG, RemingtonPL. Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Ann. Intern. Med., 163, 437–451 (2015).
   PubMed Web of Science ®Google Scholar
• Galaviz KI , WeberMB, StrausA, HawJS, NarayanKMV, AliMK. Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose. Diabetes Care, 41, 1526–1534 (2018).
   PubMed Web of Science ®Google Scholar
• Aune D , NoratT, RomundstadP, VattenLJ. Whole grain and refined grain consumption and the risk of type 2 diabetes: a systematic review and dose–response meta-analysis of cohort studies. Eur. J. Epidemiol., 28(11), 845–858 (2013).
   PubMed Web of Science ®Google Scholar
• Carter P , GrayLJ, TroughtonJ, KhuntiK, DaviesMJ. Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis. BMJ, 341, c4229 (2010).
   PubMed Web of Science ®Google Scholar
• Mattioli AV , CoppiF, MigaldiM, FarinettiA. Fruit and vegetables in hypertensive women with asymptomatic peripheral arterial disease. Clin. Nutr. ESPEN, 27, 110–112 (2018).
   PubMedGoogle Scholar
• Imamura F , O'ConnorL, YeZet al. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. BMJ, 351, h3576 (2015).
   PubMed Web of Science ®Google Scholar
• Pan A , SunQ, BernsteinAMet al. Red meat consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. Am. J. Clin. Nutr., 94(4), 1088–1096 (2011).
   PubMed Web of Science ®Google Scholar
• Allaire BT , TjadenAH, VendittiEMet al. Diet quality, weight loss, and diabetes incidence in the Diabetes Prevention Program (DPP). BMC Nutr., 6(1), 74 (2020).
   PubMedGoogle Scholar
• Low CA , ThurstonRC, MatthewsKA. Psychosocial factors in the development of heart disease in women: current research and future directions. Psychosom. Med., 72, 842–854 (2010).
   PubMed Web of Science ®Google Scholar
• Mattioli AV , NasiM, CocchiC, FarinettiA. COVID 19 outbreak: impact of the quarantine-induced stress on cardiovascular disease risk burden. Future Cardiol., 16(6), 539–542 (2020).
   PubMed Web of Science ®Google Scholar
• Brooks SK , WebsterRK, SmithLEet al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet, 395, 912–920 (2020).
   PubMed Web of Science ®Google Scholar
• Louvardi M , PelekasisP, ChrousosG, DarviriC. Mental health in chronic disease patients during the COVID-19 quarantine in Greece. Palliat. Support. Care, 8(4), 394–399 (2020).
   Google Scholar
• Mattioli AV , SciomerS, MaffeiS, GallinaS. Lifestyle and stress management in women during COVID-19 pandemic: impact on cardiovascular risk burden. Am. J. Lifestyle Med. doi:10.1177/1559827620981014 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Smati S , TramuntB, WargnyMet al. Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: results from the CORONADO study. Diabetes Obes. Metab., 23(2), 391–403 (2021).
   PubMed Web of Science ®Google Scholar
• Baidya A , SinghSK, BajajSet al. Diabetes and COVID-19: a review. J. ASEAN Fed. Endocr. Soc., 35(1), 40–48 (2020).
   PubMedGoogle Scholar
• Wells JCK . The diabesity epidemic in the light of evolution: insights from the capacity-load model. Diabetologia, 62(10), 1740–1750 (2019).
   PubMed Web of Science ®Google Scholar
• Sluik D , BuijsseB, MuckelbauerRet al. Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis. Arch. Intern. Med., 172, 1285–1295 (2012).
   PubMedGoogle Scholar
• Nasi M , PatriziG, PizziCet al. The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. J. Cardiovasc. Med., 20(10), 631–639 (2019).
   Google Scholar
• Arnett DK , BlumenthalRS, AlbertMAet al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140(11), e596–e646 (2019).
   PubMed Web of Science ®Google Scholar
• Cho L , DavisM, ElgendyIet al. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review. J. Am. Coll. Cardiol., 75(20), 2602–2618 (2020).
   PubMed Web of Science ®Google Scholar
• Jin X , ChandramouliC, AlloccoB, GongE, LamCSP, YanLL. Women's participation in cardiovascular clinical trials from 2010 to 2017. Circulation, 141, 540–548 (2020).
   PubMed Web of Science ®Google Scholar
• Gong IY , TanNS, AliSHet al. Temporal trends of women enrollment in major cardiovascular randomized clinical trials. Can. J. Cardiol., 35, 653–660 (2019).
   PubMed Web of Science ®Google Scholar
• Reza N , TahhanAS, MahmudNet al. Representation of women authors in international heart failure guidelines and contemporary clinical trials. Circ. Heart Fail., 13, e006605 (2020).
   PubMed Web of Science ®Google Scholar
• Wells JS , PughS, BoparaiK, ReardenJ, YeagerKA, BrunerDW. Cultural competency training to increase minority enrollment into radiation therapy clinical trials – an NRG oncology RTOG study. J. Cancer Educ., 32, 721–727 (2017).
   PubMed Web of Science ®Google Scholar
• Pan X , XuS, LiJ, TongN. The effects of DPP-4 inhibitors, GLP-1RAs, and SGLT-2/1 inhibitors on heart failure outcomes in diabetic patients with and without heart failure history: insights from CVOTs and drug mechanism. Front. Endocrinol., 11, 599355 (2020).
   PubMed Web of Science ®Google Scholar
• Maruthur NM , TsengE, HutflessSet al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med., 164, 740–751 (2016).
   PubMed Web of Science ®Google Scholar
• Scheen AJ , PaquotN. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab., 39, 179–190 (2013).
   PubMed Web of Science ®Google Scholar
• Mishriky BM , OkunrintemiV, JainS, SewellKA, PowellJR, CummingsDM. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis. Diabetes Metab., 47(1), 101160 (2021).
   PubMed Web of Science ®Google Scholar
• Zinman B , WannerC, LachinJMet al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med., 373(22), 2117–2128 (2015).
   PubMed Web of Science ®Google Scholar
• Neal B , PerkovicV, MahaffeyKWet al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med., 377(7), 644–657 (2017).
   PubMed Web of Science ®Google Scholar
• Norhammar A , BodegårdJ, NyströmT, ThuressonM, NathansonD, ErikssonJW. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: a nationwide observational study. Diabetes Obes. Metab., 21(5), 1136–1145 (2019).
   PubMed Web of Science ®Google Scholar
• Perkovic V , JardineMJ, NealBet al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med., 380(24), 2295–2306 (2019).
   PubMed Web of Science ®Google Scholar
• Rådholm K , ZhouZ, ClemensK, NealB, WoodwardM. Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men. Diabetes Obes. Metab., 22(2), 263–266 (2020).
   PubMed Web of Science ®Google Scholar
• Zinman B , InzucchiSE, WannerCet al. Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®. Diabetologia, 61(7), 1522–1527 (2018).
   PubMed Web of Science ®Google Scholar
• Li CX , LiangS, GaoL, LiuH. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLoS One, 16(2), e0244689 (2021).
   PubMed Web of Science ®Google Scholar